Comparison of Physical and Biochemical Characterizations of SARS-CoV-2 Inactivated by Different Treatments

Viruses. 2022 Aug 31;14(9):1938. doi: 10.3390/v14091938.

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused huge social and economic distress. Given its rapid spread and the lack of specific treatment options, SARS-CoV-2 needs to be inactivated according to strict biosafety measures during laboratory diagnostics and vaccine development. The inactivation method for SARS-CoV-2 affects research related to the natural virus and its immune activity as an antigen in vaccines. In this study, we used size exclusion chromatography, western blotting, ELISA, an electron microscope, dynamic light scattering, circular dichroism, and surface plasmon resonance to evaluate the effects of four different chemical inactivation methods on the physical and biochemical characterization of SARS-CoV-2. Formaldehyde and β-propiolactone (BPL) treatment can completely inactivate the virus and have no significant effects on the morphology of the virus. None of the four tested inactivation methods affected the secondary structure of the virus, including the α-helix, antiparallel β-sheet, parallel β-sheet, β-turn, and random coil. However, formaldehyde and long-term BPL treatment (48 h) resulted in decreased viral S protein content and increased viral particle aggregation, respectively. The BPL treatment for 24 h can completely inactivate SARS-CoV-2 with the maximum retention of the morphology, physical properties, and the biochemical properties of the potential antigens of the virus. In summary, we have established a characterization system for the comprehensive evaluation of virus inactivation technology, which has important guiding significance for the development of vaccines against SARS-CoV-2 variants and research on natural SARS-CoV-2.

Keywords: S protein; SARS-CoV-2; formaldehyde; surface plasmon resonance; virus inactivation; β-propiolactone.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Viral
  • COVID-19 Vaccines
  • COVID-19* / prevention & control
  • Formaldehyde
  • Humans
  • Propiolactone / pharmacology
  • SARS-CoV-2*
  • Vaccines, Inactivated

Substances

  • Antibodies, Viral
  • COVID-19 Vaccines
  • Vaccines, Inactivated
  • Formaldehyde
  • Propiolactone

Supplementary concepts

  • SARS-CoV-2 variants

Grants and funding

This work was supported by the Beijing Nova Program (Z201100006820128) and Beijing Science and technology plan (Z211100002521017).